- Home
- NIVF vs PTIX Comparison
NIVF vs PTIX Comparison
Compare NIVF & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- PTIX
- Stock Information
- Founded
- NIVF 2011
- PTIX 1994
- Country
- NIVF Thailand
- PTIX United States
- Employees
- NIVF N/A
- PTIX N/A
- Industry
- NIVF
- PTIX Biotechnology: Pharmaceutical Preparations
- Sector
- NIVF
- PTIX Health Care
- Exchange
- NIVF NYSE
- PTIX Nasdaq
- Market Cap
- NIVF 2.1M
- PTIX 1.9M
- IPO Year
- NIVF N/A
- PTIX 2016
- Fundamental
- Price
- NIVF $2.20
- PTIX $3.62
- Analyst Decision
- NIVF
- PTIX
- Analyst Count
- NIVF 0
- PTIX 0
- Target Price
- NIVF N/A
- PTIX N/A
- AVG Volume (30 Days)
- NIVF 7.7M
- PTIX 5.4M
- Earning Date
- NIVF 01-01-0001
- PTIX 05-13-2025
- Dividend Yield
- NIVF N/A
- PTIX N/A
- EPS Growth
- NIVF N/A
- PTIX N/A
- EPS
- NIVF N/A
- PTIX N/A
- Revenue
- NIVF $5,433,375.00
- PTIX N/A
- Revenue This Year
- NIVF N/A
- PTIX N/A
- Revenue Next Year
- NIVF N/A
- PTIX N/A
- P/E Ratio
- NIVF N/A
- PTIX N/A
- Revenue Growth
- NIVF 5.79
- PTIX N/A
- 52 Week Low
- NIVF $1.68
- PTIX $2.35
- 52 Week High
- NIVF $656.00
- PTIX $16.38
- Technical
- Relative Strength Index (RSI)
- NIVF 41.58
- PTIX 47.16
- Support Level
- NIVF $1.68
- PTIX $3.44
- Resistance Level
- NIVF $6.13
- PTIX $3.94
- Average True Range (ATR)
- NIVF 0.74
- PTIX 1.37
- MACD
- NIVF 0.10
- PTIX -0.18
- Stochastic Oscillator
- NIVF 11.69
- PTIX 1.66
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.